- Aileron Therapeutics to Present at Two Upcoming Investor Conferences
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
- Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Aileron Therapeutics Announces CEO Transition
- Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
More ▼
Key statistics
On Friday, Aileron Therapeutics Inc (ALRN:NAQ) closed at 3.82, 278.22% above the 52 week low of 1.01 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.79 |
---|---|
High | 3.99 |
Low | 3.65 |
Bid | 2.97 |
Offer | 4.60 |
Previous close | 3.82 |
Average volume | 181.38k |
---|---|
Shares outstanding | 21.14m |
Free float | 20.28m |
P/E (TTM) | -- |
Market cap | 80.76m USD |
EPS (TTM) | -3.39 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼